Chatterton B E, Ho Shon I, Baldey A, Lenzo N, Patrikeos A, Kelley B, Wong D, Ramshaw J E, Scott A M
Department of Nuclear Medicine and PET, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia.
Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):354-61. doi: 10.1007/s00259-008-0959-y. Epub 2008 Oct 18.
The aims of this study were (1) to determine the incremental information provided by (18)F-FDG positron emission tomography (PET) in staging patients with oesophageal cancer, and (2) to determine the impact of PET staging on post-PET clinical management of oesophageal cancer, and on prognosis.
In a multicentre, single-arm open study, patients with proved oesophageal cancer without definite distant metastases and regarded as suitable for potentially curative treatment were examined by PET. Clinicians were requested to supply a management plan before and another plan after being supplied with the PET scan results. Patients were followed for at least 1 year for outcome analysis.
A total of 129 patients (104 men, mean age 67 y) were recruited. PET detected additional sites of disease in 53 patients (41%). Significant changes in management (high or medium impact) were observed in 38% of patients, primarily as a result of identifying additional sites of disease and/or confirming previously equivocal regional and distant metastases. Progression-free survival was significantly shorter in patients found to have additional lesions on PET (p < 0.05), but was not related to SUV(max).
These findings demonstrate the significant impact of PET on the clinical management of patients with newly diagnosed oesophageal carcinoma, and on prognostic stratification of these patients.
本研究的目的是:(1)确定18F-FDG正电子发射断层扫描(PET)在食管癌患者分期中提供的增量信息;(2)确定PET分期对食管癌PET检查后临床管理及预后的影响。
在一项多中心、单臂开放性研究中,对确诊为食管癌且无明确远处转移、被认为适合进行潜在根治性治疗的患者进行PET检查。要求临床医生在提供PET扫描结果之前和之后分别提供一份管理计划。对患者进行至少1年的随访以进行结果分析。
共招募了129例患者(104例男性,平均年龄67岁)。PET在53例患者(41%)中检测到了额外的病变部位。38%的患者观察到管理方面有显著变化(高或中度影响),主要是由于发现了额外的病变部位和/或证实了先前不明确的区域及远处转移。PET检查发现有额外病变的患者无进展生存期显著缩短(p<0.05),但与SUV(最大值)无关。
这些发现表明PET对新诊断食管癌患者的临床管理及这些患者的预后分层有显著影响。